The Role of CD47 in Neutrophil Transmigration

Yuan Liu,Didier Merlin,Stephanie L. Burst,Mildred Pochet,James Madara,Charles A. Parkos

DOI: https://doi.org/10.1074/jbc.m104138200

2001-01-01

Abstract:CD47, a cell surface glycoprotein, plays an important role in modulating neutrophil (PMN) migration across endothelial and epithelial monolayers. Here we show that anti-CD47 monoclonal antibodies (mAbs) delay PMN migration across collagen-coated filters or T84 epithelial monolayers toward the chemoattractant formylmethionylleucylphenylalanine (fMLP). Despite delayed transmigration by anti-CD47 mAbs, the numbers of PMN migrating across in either condition were the same as in the presence of control non-inhibitory mAbs. Cell surface labeling and immunoprecipitation demonstrated upregulation of CD47 to the PMN cell surface with kinetics similar to those of the transmigration response. Subcellular fractionation studies revealed redistribution of CD47 from intracellular compartments that co-sediment with secondary granules to plasma membrane-containing fractions after fMLP stimulation. Experiments performed to investigate potential signaling pathways revealed that inhibition of tyrosine phosphorylation with genistein reversed the anti-CD47-mediated PMN migration delay, whereas inhibition of phosphatidylinositol 3-kinase only partially reversed anti-CD47 effects that correlated with a rapid increase in PMN cell surface CD47. Analysis of the contribution of epithelial-expressed CD47 to PMN transmigration revealed that PMN migration across CD47-deficient epithelial monolayers (CaCO2) was significantly increased after stable transfection with CD47. These results suggest that cell surface CD47 and downstream tyrosine phosphorylation signaling events regulate, in part, the rate of PMN migration during the inflammatory response. CD47, a cell surface glycoprotein, plays an important role in modulating neutrophil (PMN) migration across endothelial and epithelial monolayers. Here we show that anti-CD47 monoclonal antibodies (mAbs) delay PMN migration across collagen-coated filters or T84 epithelial monolayers toward the chemoattractant formylmethionylleucylphenylalanine (fMLP). Despite delayed transmigration by anti-CD47 mAbs, the numbers of PMN migrating across in either condition were the same as in the presence of control non-inhibitory mAbs. Cell surface labeling and immunoprecipitation demonstrated upregulation of CD47 to the PMN cell surface with kinetics similar to those of the transmigration response. Subcellular fractionation studies revealed redistribution of CD47 from intracellular compartments that co-sediment with secondary granules to plasma membrane-containing fractions after fMLP stimulation. Experiments performed to investigate potential signaling pathways revealed that inhibition of tyrosine phosphorylation with genistein reversed the anti-CD47-mediated PMN migration delay, whereas inhibition of phosphatidylinositol 3-kinase only partially reversed anti-CD47 effects that correlated with a rapid increase in PMN cell surface CD47. Analysis of the contribution of epithelial-expressed CD47 to PMN transmigration revealed that PMN migration across CD47-deficient epithelial monolayers (CaCO2) was significantly increased after stable transfection with CD47. These results suggest that cell surface CD47 and downstream tyrosine phosphorylation signaling events regulate, in part, the rate of PMN migration during the inflammatory response. polymorphonuclear leukocyte immunoglobulin variable domain myeloperoxidase Hanks' balanced salt buffer devoid of Ca2+ and Mg2+ formylmethionylleucylphenylalanine phosphatidylinositol 3-kinase monoclonal antibody Dulbecco's modified Eagle's medium junction adhesion molecule thrombospondin-1 fluorescence-activated cell sorting protein kinase C mitogen-activated protein kinase/extracellular signal-regulated kinase kinase fluorescein isothiocyanate polymerase chain reaction alkaline phosphatase In many inflammatory conditions, large numbers of PMN1migrate across vascular endothelium, cell matrix, and mucosal surfaces in response to chemotactic signals. Under these conditions, PMN release active oxygen species, proteolytic enzymes, and inflammatory mediators that result in tissue injury. Thus, it is intuitive that large scale PMN migration and accumulation in tissues correlates with disease activity and patient symptoms (1Stockley R.A. Am. J. Med. 1995; 99: 8S-13SAbstract Full Text PDF PubMed Scopus (47) Google Scholar,2Kumar N.B. Nostrant T.T. Appelman H.D. Am. J. Surg. Pathol. 1982; 6: 523-529Crossref PubMed Scopus (142) Google Scholar). The process of PMN movement from the vasculature, through the interstitial matrix, and across mucosal surfaces requires sequential interactions between neutrophil surface molecules and counter-receptors present on tissues or cell surfaces (3Parkos C.A. Bioessays. 1997; 19: 865-873Crossref PubMed Scopus (67) Google Scholar, 4Lawrence M.B. Springer T.A. Cell. 1991; 65: 859-873Abstract Full Text PDF PubMed Scopus (1887) Google Scholar, 5Muller W.A. Weigl S.A. Deng X. Phillips D.M. J. Exp. Med. 1993; 178: 449-460Crossref PubMed Scopus (990) Google Scholar, 6Spertini O. Kansas G.S. Munro J.M. Griffin J.D. Tedder T.F. Nature. 1991; 349: 691-694Crossref PubMed Scopus (235) Google Scholar). Previous studies have shown that the leukocyte β2 integrin CD11bCD18 is essential in this process, especially in early interactions with epithelial and endothelial cells during the transmigration response (3Parkos C.A. Bioessays. 1997; 19: 865-873Crossref PubMed Scopus (67) Google Scholar,7Diamond M.S. Alon R. Parkos C.A. Quinn M.T. Springer T.A. J. Cell Biol. 1995; 130: 1473-1482Crossref PubMed Scopus (255) Google Scholar, 8von Andrian U.H. Chambers J.D. McEvoy L.M. Bargatze R.F. Arfors K.E. Butcher E.C. Proc. Natl. Acad. Sci. U. S. A. 1991; 88: 7538-7542Crossref PubMed Scopus (901) Google Scholar). Although PMN migration across endothelial monolayers is only partially blocked by anti-CD11bCD18 antibodies, there is near complete inhibition of PMN migration across epithelial monolayers by the same antibodies (9Parkos C.A. Delp C. Arnaout M.A. Madara J.L. J. Clin. Invest. 1991; 88: 1605-1612Crossref PubMed Scopus (292) Google Scholar). The importance of β2 integrins in PMN transmigration is manifested clinically by patients with leukocyte adhesion deficiency who lack β2 integrins, resulting in a failure of PMN to migrate out of the vasculature and leaving high levels of circulating PMN (10Anderson D.C. Schmalstieg F.C. Arnaout M.A. Kohl S. Tosi M.F. Dana N. Buffone G.J. Hughes B.J. Brinkley B.R. Dickey W.D. et al.J. Clin. Invest. 1984; 74: 536-551Crossref PubMed Scopus (159) Google Scholar, 11Dana N. Todd R.F. d. Pitt J. Springer T.A. Arnaout M.A. J. Clin. Investig. 1984; 73: 153-159Crossref PubMed Scopus (111) Google Scholar). A second protein that has been shown to play an important role in PMN transmigration is CD47 (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). PMN migration across both epithelial and endothelial monolayers can be inhibited by anti-CD47 antibodies (3Parkos C.A. Bioessays. 1997; 19: 865-873Crossref PubMed Scopus (67) Google Scholar, 12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar, 13Cooper D. Lindberg F.P. Gamble J.R. Brown E.J. Vadas M.A. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 3978-3982Crossref PubMed Scopus (185) Google Scholar). CD47 was originally defined as a tumor-specific marker for ovarian carcinoma but is now known to be widely expressed on all hematopoietic cells and most other cell types (14Mawby W.J. Holmes C.H. Anstee D.J. Spring F.A. Tanner M.J. Biochem. J. 1994; 304: 525-530Crossref PubMed Scopus (114) Google Scholar, 15Lindberg F.P. Gresham H.D. Schwarz E. Brown E.J. J. Cell Biol. 1993; 123: 485-496Crossref PubMed Scopus (307) Google Scholar, 16Reinhold M.I. Lindberg F.P. Plas D. Reynolds S. Peters M.G. Brown E.J. J. Cell Sci. 1995; 108: 3419-3425Crossref PubMed Google Scholar). The primary structure of human and mouse CD47 predicts the protein containing an N-terminal extracellular IgV domain, a membrane-spanning domain with multiple transmembrane α helices, and an intracellular loop (15Lindberg F.P. Gresham H.D. Schwarz E. Brown E.J. J. Cell Biol. 1993; 123: 485-496Crossref PubMed Scopus (307) Google Scholar). In addition to regulating PMN transmigration, other studies have implicated CD47 in multiple cellular functions. In particular, antibodies to CD47 have been shown to interfere with αvβ3-mediated cell functions (15Lindberg F.P. Gresham H.D. Schwarz E. Brown E.J. J. Cell Biol. 1993; 123: 485-496Crossref PubMed Scopus (307) Google Scholar), as well as to block endothelial Ca2+ influxes during adhesion to fibronectin- or vitronectin-coated surfaces (17Schwartz M.A. Brown E.J. Fazeli B. J. Biol. Chem. 1993; 268: 19931-19934Abstract Full Text PDF PubMed Google Scholar). CD47 has been shown to bind to the C terminus of thrombospondin-1 (18Gao A.G. Lindberg F.P. Finn M.B. Blystone S.D. Brown E.J. Frazier W.A. J. Biol. Chem. 1996; 271: 21-24Abstract Full Text Full Text PDF PubMed Scopus (332) Google Scholar), therefore suggesting a role in platelet activation. Anti-CD47 antibodies have also been used to implicate CD47 in T cell activation (19Waclavicek M. Majdic O. Stulnig T. Berger M. Baumruker T. Knapp W. Pickl W.F. J. Immunol. 1997; 159: 5345-5354PubMed Google Scholar, 20Reinhold M.I. Lindberg F.P. Kersh G.J. Allen P.M. Brown E.J. J. Exp. Med. 1997; 185: 1-11Crossref PubMed Scopus (140) Google Scholar), T and B cell apoptosis (21Pettersen R.D. Hestdal K. Olafsen M.K. Lie S.O. Lindberg F.P. J. Immunol. 1999; 162: 7031-7040PubMed Google Scholar, 22Mateo V. Lagneaux L. Bron D. Biron G. Armant M. Delespesse G. Sarfati M. Nat. Med. 1999; 5: 1277-1284Crossref PubMed Scopus (198) Google Scholar), and stroma-supported erythropoiesis (23Furusawa T. Yanai N. Hara T. Miyajima A. Obinata M. J. Biochem. 1998; 123: 101-106Crossref PubMed Scopus (23) Google Scholar). Recently, CD47 has been shown to bind to P84 (also termed SIRPα, Bit, SHPS-1, and MFR) (24Jiang P. Lagenaur C.F. Narayanan V. J. Biol. Chem. 1999; 274: 559-562Abstract Full Text Full Text PDF PubMed Scopus (275) Google Scholar, 25Seiffert M. Cant C. Chen Z. Rappold I. Brugger W. Kanz L. Brown E.J. Ullrich A. Buhring H.J. Blood. 1999; 94: 3633-3643Crossref PubMed Google Scholar, 26Vernon-Wilson E.F. Kee W.J. Willis A.C. Barclay A.N. Simmons D.L. Brown M.H. Eur. J. Immunol. 2000; 30: 2130-2137PubMed Google Scholar), and this interaction has been broadly implicated in the regulation of memory formation, macrophage multinucleation, B cell aggregation, and red blood cell self-recognition in mice (27Babic I. Schallhorn A. Lindberg F.P. Jirik F.R. J. Immunol. 2000; 164: 3652-3658Crossref PubMed Scopus (47) Google Scholar, 28Oldenborg P.A. Zheleznyak A. Fang Y.F. Lagenaur C.F. Gresham H.D. Lindberg F.P. Science. 2000; 288: 2051-2054Crossref PubMed Scopus (1313) Google Scholar). Despite the diverse array of functional studies on CD47, the biochemical/molecular mechanism(s) of CD47 function remain undefined. Although we have previously observed anti-CD47 antibody-mediated inhibition of PMN transmigration (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar), the molecular basis of this effect is not clear. The objective of the current study was to investigate the mechanism of CD47 function in PMN migration across epithelial cell monolayers and collagen-coated filters. Using a time-course transmigration assay, we demonstrate that fMLP-driven PMN migration across epithelial monolayers and collagen-coated filters is significantly delayed after cell surface CD47 is blocked by functionally inhibitory anti-CD47 mAbs. However, despite delayed transmigration caused by anti-CD47 mAbs, the number of PMN that eventually migrate is the same as that observed with isotype-matched binding controls. Cell surface labeling and immunoprecipitation experiments demonstrate increased CD47 on the PMN cell surface after stimulation with fMLP and after transmigration. PMN subcellular fractionation experiments revealed that increased cell surface CD47 is derived from intracellular membranes that co-sediment with the secondary (specific) granules. Experiments performed to investigate potential signaling pathways revealed that inhibition of PI3K partially reversed anti-CD47 mediated inhibition of migration while also directly enhancing the rate of PMN migration in a fashion that paralleled a rapid increase of PMN cell surface CD47. Additional inhibitor studies revealed that tyrosine phosphorylation inhibition by genistein reversed anti-CD47 effect in a near complete fashion. In further support of the notion that cell surface CD47 positively regulates the rate of migration, we found that transfection of CD47 into deficient epithelial cells (CaCO2) results in enhanced PMN transepithelial migration. Taken together, these results suggest that translocation of CD47 to the cell surface and tyrosine kinase-mediated signaling events are key components that determine the rate of PMN migration in an inflammatory response. T84 cells (passages 60–80) were grown in a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's F-12 medium supplemented with 15 mm HEPES buffer (pH 7.5), 14 mm NaHCO3, 40 µg/ml penicillin, 8 µg/ml ampicillin, 90 µg/ml streptomycin, and 6% newborn calf serum. Cells were subcultured or harvested every 6–8 days with 0.1% trypsin and 1.0 mm EDTA in Ca2+ and Mg2+-free phosphate-buffered saline. For transmigration experiments, T84 cells were grown on collagen-coated, permeable polycarbonate filters (5-µm pore size) with a surface area of 0.33 cm2 (Costar, Cambridge, MA) as previously described (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). CaCO2 cells were cultured in DMEM supplemented with 10% fetal bovine serum. Transfected CaCO2 cells (CaCO2-pCB6 and CaCO2-CD47) were maintained in the same medium containing 1 mg/ml G418. PMN were isolated from whole blood of normal human volunteers as previously described (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). Isolated PMN were resuspended in modified Hanks' balanced salt solution devoid of calcium or magnesium (HBSS(−)) (4 °C) at a concentration of 5 × 107 cells/ml and used within 4 h of isolation. C5D5, a functionally inhibitory mAb (IgG1) was produced in our laboratory as previously reported (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). B6H12.2, another functionally inhibitory anti-CD47 mAb (IgG1) (13Cooper D. Lindberg F.P. Gamble J.R. Brown E.J. Vadas M.A. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 3978-3982Crossref PubMed Scopus (185) Google Scholar) was purified from supernatants of hybridoma cells obtained from the American Tissue Culture Co. CD47 mAbs PF2.1, PF3.1, and PF10.2 were produced in our laboratory by immunizing female balb/C mice with CD47 immunopurified from 50 g of human spleen cells using previously described methods (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). Splenocytes from immunized mice were fused with P3U1 myeloma cells and cultured in selection media containing DBA-2 feeder thymocytes. Hybridoma supernatants were screened for reactivity with purified CD47 by enzyme-linked immunosorbent assay in concert with cell surface staining by immunofluorescence and flow cytometry on T84 epithelial cells and PMN. Hybridomas were then subcloned by limiting dilution, weaned from selection media, and injected into the peritoneal cavities of balb/C mice for ascites fluid production. Antibodies were purified using protein-A-Sepharose affinity chromatography and dialyzed against 150 mm NaCl, 10 mm HEPES, pH 7.4. Monoclonal antibody PF3.1 was coupled to CNBr-activated Sepharose at 2–3 mg/ml described by the manufacturer (Amersham Pharmacia Biotech) and used for immunoprecipitation of CD47. A polyclonal antibody (R12989) was also produced by immunizing rabbits with synthetic peptide SNQKTIQPPRNN, corresponding to a region of the putative C terminus of CD47 (15Lindberg F.P. Gresham H.D. Schwarz E. Brown E.J. J. Cell Biol. 1993; 123: 485-496Crossref PubMed Scopus (307) Google Scholar). As a non-inhibitory binding control, mAb J3F.1 (mouse IgG1) reactive with human junction adhesion molecule (JAM) was used (29Liu Y. Nusrat A. Schnell F.J. Reaves T.A. Walsh S. Pochet M. Parkos C.A. J. Cell Sci. 2000; 113: 2363-2374Crossref PubMed Google Scholar). Similar to CD47, JAM is a transmembrane IgV superfamily member expressed on the surfaces of both PMN and epithelial cells (29Liu Y. Nusrat A. Schnell F.J. Reaves T.A. Walsh S. Pochet M. Parkos C.A. J. Cell Sci. 2000; 113: 2363-2374Crossref PubMed Google Scholar). As a positive functionally inhibitory control, anti-CD11b mAb CBMR1/29, was used (30Balsam L.B. Liang T.W. Parkos C.A. J. Immunol. 1998; 160: 5058-5065PubMed Google Scholar). Anti-β3 integrin mAbs 15, 33, 27, and LIBs-1 were kind gifts from Dr. Mark Ginsberg. LM609 was kindly provided by Dr. David Cherish. An additional anti-β3 mAb AP1 was purchased from GTI Inc. A functionally blocking mAb to β1 integrin, mAb 13, was kindly provided by Dr. Kenneth Yamada. Purified human thrombospondin-1 (TS1) and anti-TS1 polyclonal antibody R1 were kindly provided by Dr. Jack Lawler (31Sipes J.M. Krutzsch H.C. Lawler J. Roberts D.D. J. Biol. Chem. 1999; 274: 22755-22762Abstract Full Text Full Text PDF PubMed Scopus (55) Google Scholar). Rabbit polyclonal antibody against human CD11b R7928A was raised by immunizing rabbit with a peptide (DMMSEGGPPGAEPQ) corresponding to the C terminus of CD11b. Peptide 4N1K (KRFYVVMWKK) corresponding to the C-terminal cell binding domain of thrombospondin, which has previously been shown to bind to CD47-transfected cells (18Gao A.G. Lindberg F.P. Finn M.B. Blystone S.D. Brown E.J. Frazier W.A. J. Biol. Chem. 1996; 271: 21-24Abstract Full Text Full Text PDF PubMed Scopus (332) Google Scholar, 32Wang X.Q. Frazier W.A. Mol. Biol. Cell. 1998; 9: 865-874Crossref PubMed Scopus (140) Google Scholar), was synthesized and high performance liquid chromatography-purified to >90% by the Emory Microchemical Facility. PMN transepithelial migration experiments were performed using epithelial monolayers as previously described (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). Briefly, confluent T84 or CaCO2 monolayers were washed twice with HBSS (20 °C). PMN (1 × 106) in 150 µl of HBSS with or without antibody was added to the upper chamber of the monolayer setup. Transmigration was initiated by adding 1 ml of 1 µm fMLP (in HBSS) into the lower chamber followed by incubation at 37 °C. PMN migration across monolayers into the fMLP-containing lower chambers was quantified by myeloperoxidase (MPO) assay as previously described (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). To assay the time course of PMN transmigration, the upper chambers of Transwell devices containing PMN and monolayers were gently moved to new wells containing 1 ml of 1 µm fMLP in 24-well plates at every 30 min as depicted in Fig. 1. PMN migration into the lower chambers at the different time periods was then analyzed by MPO assay. To assay the PMN associated with epithelial monolayers, transmigration was stopped at different time points, and monolayers were washed with HBSS and lysed with 0.5% Triton X-100. Monolayer lysates were then assayed for myeloperoxidase. Apical to basolateral PMN transepithelial migration was performed similarly except that twice as many PMN (2 × 106) were added onto the upper chamber. Additional transmigration experiments were performed using collagen-coated filters devoid of epithelial cells. For these experiments, 20 µl of a PMN suspension containing 1 × 106 cells was stimulated to transmigrate from the upper chamber to the lower chamber containing 0.1 µm fMLP. A number of signal transduction pathway inhibitors were tested for the ability to reverse the effects of anti-CD47 mAbs on PMN transmigration. For these experiments, PMN were pre-treated for 15–60 min with the following agents prior to use in transfilter migration assays: 50–100 nm wortmannin or 20–100 µm LY294002 (PI3K inhibitor (Sigma Chemical Co.)), 0.5 µm straurosporine (PKC and other kinases inhibitor (Biomol)), 10–200 µg/ml genistein (tyrosine phosphorylation inhibitor) and its analog daidzein (both from Biomol), 0.1 µm AG126 (tyrosine phosphorylation inhibitor (Biomol)), 40 µm PP1 (Src family tyrosine kinase inhibitor (Biomol)), 20 µm SB203580 (mitogen-activated protein kinase inhibitor (Biomol)), 20 µm PD-98059 (MEK inhibitor (Biomol)), 10 µmU73122 (phospholipase C inhibitor (Biomol)), 1 mm propranolol (phospholipase D inhibitor (Biomol)), 1 µm GF109203X (PKC inhibitor (Biomol)), 20 µm AG490 (Jak kinase inhibitor (Biomol)), 20 µm H-8 (PKA/G inhibitor (Biomol)), 10 µm H-89 (PKA inhibitor (Biomol)), etc. Control migration was done in the presence of the same dilution of vehicle (Me2SO) in HBSS. For G-protein pathway inhibition experiments, PMN were pre-treated with 200–2000 ng/ml pertussis toxin (Calbiochem) for 2 h at 37 °C before use in migration assays. Surface CD47 labeling was performed by incubation of 100 µl of non-permeabilized PMN (5 × 106 cells) with anti-CD47 mAb C5D5 (20 µg/ml) for 1 h at 4 °C in HBSS after blocking nonspecific binding with 0.5% bovine serum albumin. After washing, PMN were incubated with FITC-conjugated goat anti-mouse secondary antibody (1:200 dilution in HBSS) (PharMingen) for 30 min at 4 °C followed by wash before flow cytometric analysis. CD47 labeling in this condition was compared to that obtained with normal mouse IgG1. To assay PMN surface CD47 expression during transmigration, PMN that remained in the upper chambers or had migrated into the lower chambers of Transwell setups were cooled on ice after various migration time periods followed by antibody labeling and flow cytometry. Cell surface CD47 on PMN was also assessed after PMN were stimulated with fMLP. In these experiments, 5 × 106 PMN in 2 ml of HBSS were allowed to settle in 24-well or 6-well non-tissue culture plates at room temperature for 5 min. fMLP was then added (50 nm) followed by incubation at 37 °C for various time periods. Cells were then chilled on ice and labeling performed as above. PMN (1.5 × 107/ml), in suspension or adherent to 6-well plates, were stimulated with fMLP followed by cell surface biotinylation with 0.5 mg of sulfo-NHS-Biotin (Pierce) in 1 ml of HBSS for 1 h on ice. Excess free Biotin was washed off and quenched with 100 mmNH4Cl. Cells were then solubilized with lysis buffer containing 150 mm NaCl, 2 mmCaCl2, 2 mm Mg Cl2, 1% Triton, 2 µg/ml aprotinin, 1 mm phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, and 1 µg/ml pepstatin. Cell lysates (200–400 µg of total protein) were precleared with control IgG before incubation with 10 µl of PF3.1-Sepharose (conjugated at 2 mg of antibody/ml of Sepharose) for 3 h (4 °C). Washed immunoprecipitates were boiled in 100 µl of sample buffer and subjected to SDS-polyacrylamide gel electrophoresis followed by transfer to nitrocellulose. Nonspecific binding was blocked by 5% nonfat dry milk in TTBS (50 mm Tris. HCl, 200 nm NaCl, 0.05% Tween 20, pH 7.4). Biotin-labeled cell surface CD47 was detected with streptavidin-peroxidase followed by enhanced chemiluminescence (ECL (Amersham Pharmacia Biotech)). Total CD47 was detected by blotting with polyclonal rabbit anti-CD47 antibody R12989 (1:200) and was visualized with peroxidase-conjugated goat anti-rabbit secondary and ECL. Freshly isolated, unstimulated, and fMLP-stimulated PMN (2 × 108/per condition) were resuspended in 5 ml of nitrogen cavitation buffer (0.34m sucrose, 10 mm Hepes, 1 mm EDTA, 0.1 mm MgCl2, 1 mmNa2ATP, pH 7.4) followed by lysis by nitrogen cavitation (15 min, 400 p.s.i.) (4 °C). The lysates were centrifuged (1000 × g) and supernatants were then subjected to isopycnic sucrose density gradient fractionation on linear 20–55% sucrose gradients in a Beckman SW-28 swinging bucket rotor (100,000 × g; 3 h, 4 °C) exactly as previously described (33Parkos C.A. Cochrane C.G. Schmitt M. Jesaitis A.J. J. Biol. Chem. 1985; 260: 6541-6547Abstract Full Text PDF PubMed Google Scholar). 1.5-ml fractions were collected from each gradient and analyzed for sucrose density, protein, plasma membrane (alkaline phosphatase), primary granules (myeloperoxidase), and secondary granules (lactoferrin) as previously described (33Parkos C.A. Cochrane C.G. Schmitt M. Jesaitis A.J. J. Biol. Chem. 1985; 260: 6541-6547Abstract Full Text PDF PubMed Google Scholar). The entire protein coding region of CD47 was PCR-amplified from reverse-transcribed human colonic cDNA with primers C3 (sense) (5′-atgataagcttcctgcatgtggcccctggtagcg) and C6 (antisense) (5′-agcttctagactactctccaaatcggagtccat) located at the 5′-untranslated repeat and 3′-untranslated repeat, respectively. Amplified PCR product was digested with HindIII/XbaI and cloned into pCB6, which had been predigested with the same restriction endonucleases. CaCO2 cells were transfected with pCB6-CD47 or pCB6 (control transfection) using Lipofectin reagent as described by the manufacturer (Life Technologies, Inc.). Stable transfectants were selected by culturing in DMEM containing 1.2 mg/ml Geneticin (Life Technologies, Inc.). Cell surface expression of CD47 was confirmed by immunofluorescence labeling and FACS analysis. The putative extracellular domain of human CD47, including the signal peptide, was PCR-amplified by primers C3(5′-atgataagcttcctgcatgtggcccctggtagcgg) and C4 (5′-ttgattagatctatttggagaaaaccatga) from reverse-transcribed T84 cDNA. The DNA fragment was cloned into the mammalian expression vector AP-tag2 (34Cheng H.J. Flanagan J.G. Cell. 1994; 79: 157-168Abstract Full Text PDF PubMed Scopus (328) Google Scholar), which contains the catalytic domain of human placental alkaline phosphatase (AP) at the C terminus, throughBglII and HindIII restriction sites. After transformation, at least three independent clones were isolated and the entire protein-coding region was confirmed by DNA sequencing. Transient transfections of COS-7 were performed using a standard DEAE-dextran method (35Liu Y. The Mechanism of GAG Autoproteolytic Activation and Enzyme Catalysis.Ph.D. dissertation. University of South Alabama, Mobile, AL1997Google Scholar). Protein expression and secretion was monitored by assaying AP activity in cell culture medium (34Cheng H.J. Flanagan J.G. Cell. 1994; 79: 157-168Abstract Full Text PDF PubMed Scopus (328) Google Scholar). Expressed CD47-AP fusion protein in medium was affinity-purified by PF3.1-Sepharose and eluted with 10 mm TEA/HCl buffer containing 100 mmNaCl, pH 10.5, followed by neutralization, concentration, and dialysis. Previously, we demonstrated that anti-CD47 mAb C5D5 inhibited PMN migration across T84 monolayers (12Parkos C.A. Colgan S.P. Liang T.W. Nusrat A. Bacarra A.E. Carnes D.K. Madara J.L. J. Cell Biol. 1996; 132: 437-450Crossref PubMed Scopus (183) Google Scholar). However, we noticed that the efficiency of inhibition by C5D5 or another anti-CD47 antibody, B6H12.2 (13Cooper D. Lindberg F.P. Gamble J.R. Brown E.J. Vadas M.A. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 3978-3982Crossref PubMed Scopus (185) Google Scholar), was variable in the standard transmigration assays typically consisting of a single time point (normally 2 h). We surmised that the variable inhibition observed might be the result of differences in PMN motility after CD47 inhibition. To address this and further investigate the mechanism of CD47-mediated migration, we modified the in vitro transepithelial migration assay in which PMN migration was assessed at several time points (Fig. 1). Using this assay setup, we tested the effect of inhibitory anti-CD47 mAbs C5D5 and B6H12.2 on the time course of PMN migration across T84 monolayers. As controls, parallel experiments were performed with binding, non-inhibitory isotype-matched anti-JAM mAb J3F.1 (29Liu Y. Nusrat A. Schnell F.J. Reaves T.A. Walsh S. Pochet M. Parkos C.A. J. Cell Sci. 2000; 113: 2363-2374Crossref PubMed Google Scholar) and an inhibitory control antibody reactive with CD11b CD18 (CBRM1/29 (30Balsam L.B. Liang T.W. Parkos C.A. J. Immunol. 1998; 160: 5058-5065PubMed Google Scholar)). As shown in Fig. 2A, in the presence of control non-inhibitory mAbs, less than 10% of the total applied PMN migrated across T84 monolayers during the first 30 min (5.8 ± 0.6% for no antibody and 6.1 ± 2.0% for J3F.1). Massive PMN migration across T84 monolayers occurred during the next 30-min period (2nd 30′) with ∼40% of the applied PMN migrating into the lower chambers (43.6 ± 3.7% for no antibody and 38.7 ± 4.4% for J3F.1). In the third 30-min period (3rd 30′), PMN migration into the lower chamber decreased to 14.6 ± 2.9% for no antibody and 16.8 ± 5.2% for J3F.1. In subsequent time periods, PMN migration across the monolayers continued to decrease to <10% in the fourth 30 min and to <5% in the fifth and sixth 30-min periods, respectively. From Fig. 2 A, total migration of PMN into the lower chamber can be plotted as a function of migration time, which is shown in Fig. 2 B. As can be seen, under non-in